Meeting
2021 ASCO Annual Meeting
A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.
Authors
Martin Wermke
Department of Thoracic Oncology, Carl-Gustav-Carus Dresden University Hospital, Dresden, Germany
Martin Wermke , Enriqueta Felip , Valentina Gambardella , Yasutoshi Kuboki , Daniel Morgensztern , Zohra Oum'Hamed , Junxian Geng , Matus Studeny , Taofeek K. Owonikoko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04429087
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS8588)
DOI
10.1200/JCO.2021.39.15_suppl.TPS8588
Abstract #
TPS8588
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2019 ASCO Annual Meeting
Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
First Author: Marie-Anne Damiette Smit
Poster
2019 ASCO Annual Meeting
Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).
First Author: Hiroaki Akamatsu
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran